Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Resistance to Single-Agent Chemotherapy and Its Risk Factors in Low-Risk Gestational Trophoblastic Neoplasms Publisher Pubmed



Mousavi AS1 ; Zamani A1, 2 ; Khorasanizadeh F3, 4 ; Gilani MM1 ; Zendehdel K4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Gynecology Oncology Department, Valiasr Hospital, Imam Khomeini Hospital Complex, A'lam-Al-Hoda St, Shahid Shiroodi St, Arak, Markazi Province, 3819693345, Iran
  2. 2. Gynecology Oncology Department, Taleghani Hospital, Arak University of Medical Sciences, Arak, Iran
  3. 3. Stdnts. Scientific Research Center, Tehran, Iran
  4. 4. Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Obstetrics and Gynaecology Research Published:2015


Abstract

Aim Gestational trophoblastic neoplasm (GTN) is a rare disease which is classified into high- and low-risk groups. While the high-risk patients require combination therapy, the low-risk groups respond to single-agent chemotherapy. We studied resistance to single-agent chemotherapy and its risk factors among the low-risk GTN patients in Iran. Methods We followed 168 low-risk GTN patients who were treated between 2001 and 2011 in Valiasr Hospital, Tehran, Iran. We used a case-control design and studied odds ratios (OR) and corresponding 95% confidence intervals (CI) to evaluate association between drug resistance and different personal and clinical variables. Results Resistance to sequential single-agent chemotherapy was 19%, although all patients had a complete remission after a combination of chemotherapy and/or surgery. Patients who had International Federation of Gynecology and Obstetrics scores of 5-6 - considered as, the intermediate risk group - had a 14-fold higher resistance compared with the low score patients (OR = 14.28, 95% CI = 5.54-36.81). We found higher risk of resistance among patients with metastasis (OR = 8.42, 95% CI = 2.44-29.07), large tumor size (>3 cm) (OR = 7.73, 95% CI = 1.93-30.91), high β-hCG (>100 000 IU/L) (OR = 5.86, 95% CI = 1.07-32.02) and/or a diagnosis more than 4 months after pregnancy (OR = 3.30, 95% CI = 1.08-10.02), compared with their reference group. We found no priority for the different chemotherapy regimens. Conclusion Intermediate risk GTN patients had a higher risk of resistance to chemotherapy compared with low-risk patients. Clinical trials and cost-effectiveness studies are needed to suggest a better treatment program for the intermediate risk group. © 2014 The Authors. Journal of Obstetrics and Gynaecology Research © 2014 Japan Society of Obstetrics and Gynecology.